Alyeska Investment Group, L.P. Context Therapeutics Inc. Transaction History
Alyeska Investment Group, L.P.
- $25 Billion
- Q4 2024
A detailed history of Alyeska Investment Group, L.P. transactions in Context Therapeutics Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 1,663,355 shares of CNTX stock, worth $1.41 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,663,355
Previous 1,663,655
0.02%
Holding current value
$1.41 Million
Previous $3.26 Million
49.51%
% of portfolio
0.01%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding CNTX
# of Institutions
55Shares Held
72.9MCall Options Held
0Put Options Held
0-
Bio Impact Capital LLC Cambridge, MA14.7MShares$12.5 Million2.18% of portfolio
-
Avidity Partners Management LP Dallas, TX7.48MShares$6.36 Million0.84% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.42MShares$6.31 Million0.32% of portfolio
-
Nextech Invest Ag7.42MShares$6.31 Million1.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY6.36MShares$5.4 Million2.69% of portfolio
About Context Therapeutics Inc.
- Ticker CNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,966,100
- Market Cap $13.6M
- Description
- Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...